TScan Therapeutics Statistics
Want to see TCRX full AI Analyst Report?
TScan Therapeutics (TCRX) Stock Statistics & Valuation Metrics
Total Valuation
TScan Therapeutics has a market cap or net worth of $11.39M. The enterprise value is $57.13M.
- Market Cap
- $11.39M
- Enterprise Value
- $57.13M
Share Statistics
TScan Therapeutics has 63,502,660 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 63,502,660
- Owned by Insiders
- 16.81%
- Owned by Institutions
- 10.93%
Financial Efficiency
TScan Therapeutics’s return on equity (ROE) is -1.05 and return on invested capital (ROIC) is -62.51%.
- Return on Equity (ROE)
- -1.05
- Return on Assets (ROA)
- -0.57
- Return on Invested Capital (ROIC)
- -62.51%
- Return on Capital Employed (ROCE)
- -0.65
- Revenue Per Employee
- 74.82K
- Profits Per Employee
- -940.33K
- Employee Count
- 138
- Asset Turnover
- 0.05
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of TScan Therapeutics is -0.18. TScan Therapeutics’s PEG ratio is -0.01.
- PE Ratio
- -0.18
- PS Ratio
- 1.97
- PB Ratio
- 0.55
- Price to FCF
- -0.09
- Price to Operating Cash Flow
- -0.19
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, TScan Therapeutics had revenue of 10.32M and earned -129.77M in profits. Earnings per share was -1.00.
- Revenue
- 10.32M
- Gross Profit
- 7.46M
- Operating Income
- -135.81M
- Pretax Income
- -129.77M
- Net Income
- -129.77M
- EBITDA
- -124.13M
- Earnings Per Share (EPS)
- -1.00
Cash Flow
In the last 12 months, operating cash flow was -110.89M and capital expenditures -775,000, giving a free cash flow of -111.67M billion.
- Operating Cash Flow
- -110.89M
- Free Cash Flow
- -111.67M
- Free Cash Flow per Share
- -0.86
Dividends & Yields
TScan Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1094.94%
- Earnings Yield
- -551.13%
Stock Price Statistics
- Beta
- 2.02
- 52-Week Price Change
- -85.84%
- 50-Day Moving Average
- 0.27
- 200-Day Moving Average
- 0.81
- Relative Strength Index (RSI)
- 31.20
- Average Volume (3m)
- 755.64K
Important Dates
TScan Therapeutics upcoming earnings date is Mar 10, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- Mar 10, 2027
- Ex-Dividend Date
- ―
Financial Position
TScan Therapeutics as a current ratio of 8.41, with Debt / Equity ratio of 76.46%
- Current Ratio
- 8.41
- Quick Ratio
- 8.41
- Debt to Market Cap
- 0.25
- Net Debt to EBITDA
- 0.47
- Interest Coverage Ratio
- -49.05
Taxes
In the past 12 months, TScan Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
TScan Therapeutics EV to EBITDA ratio is -0.08, with an EV/FCF ratio of -0.08.
- EV to Sales
- 1.77
- EV to EBITDA
- -0.08
- EV to Free Cash Flow
- -0.08
- EV to Operating Cash Flow
- -0.08
Balance Sheet
TScan Therapeutics has $73.04M in cash and marketable securities with $89.28M in debt, giving a net cash position of -$16.24M billion.
- Cash & Marketable Securities
- $73.04M
- Total Debt
- $89.28M
- Net Cash
- -$16.24M
- Net Cash Per Share
- -$0.26
- Tangible Book Value Per Share
- $0.29
Margins
Gross margin is -561.59%, with operating margin of -2246.84%, and net profit margin of -2219.19%.
- Gross Margin
- -561.59%
- Operating Margin
- -2246.84%
- Pretax Margin
- -2219.19%
- Net Profit Margin
- -2219.19%
- EBITDA Margin
- -2110.08%
- EBIT Margin
- -2163.94%
Analyst Forecast
The average price target for TScan Therapeutics is $1.00, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- $1.00
- Price Target Upside
- 525.00% Upside
- Analyst Consensus
- Neutral
- Analyst Count
- 5
- Revenue Growth Forecast
- -38.43%
- EPS Growth Forecast
- 20.89%
Scores
- Smart Score
- ―
- AI Score
- 39
